BioCentury | Mar 9, 2021
Product Development

AnaptysBio looks ahead to other indications after Phase II miss in palmoplantar pustulosis

...psoriasis (GPP), where IL-36 signaling has a clearer role in driving disease. Shares of AnaptysBio Inc. (NASDAQ:ANAB...
BioCentury | Mar 9, 2021
Politics, Policy & Law

Biopharmas ask Biden to reject compulsory licensing of COVID-19 medicines

...NASDAQ:GILD), GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), Merck & Co. Inc. (NYSE:MRK), Pfizer Inc. (NYSE:PFE), Sanofi (Euronext:SAN; NASDAQ:SNY...
BioCentury | Mar 9, 2021
Product Development

New modality deep dive; plus Sharpless speaks & Five Prime scores: a BioCentury podcast

...2017, when Kadcyla ado-trastuzumab emtansine from Roche (SIX:ROG; OTCQX:RHHBY) and Adcetris brentuximab vedotin from  Seagen Inc. (NASDAQ:SGEN...
...Executive Editor Jeff Cranmer discusses the acquisition of Five Prime Therapeutics Inc. (NASDAQ:FPRX) by Amgen Inc. (NASDAQ:AMGN...
BioCentury | Mar 8, 2021
Management Tracks

ArsenalBio bolsters team via hirings of Sirichoke, Schroer; plus Moderna, Jubilant and Synlogic

...quality head at Novartis AG (NYSE:NVS; SIX:NOVN). Schroer previously was CFO at Translate Bio Inc. (NASDAQ:TBIO...
...of tools the company thinks could overcome hurdles to cell therapy for solid tumors. Moderna Inc. (NASDAQ:MRNA...
...Rastelli was CSO at Kleo Pharmaceuticals Inc. and VP of oncology at BioXcel Therapeutics Inc. (NASDAQ:BTAI). Jubilant...
BioCentury | Mar 8, 2021
Deals

March 8 Quick Takes: Roivant to acquire Immunovant; plus Lilly-Biolojic, Soleno, Gilead, Genentech and Cara-Vifor

...By BioCentury Staff Immunovant Inc. (NASDAQ:IMVT) rose $1.88 (14%) to $15.39 on Monday after the autoimmune...
...to Biolojic equity, plus royalties.FDA requests additional trial from Soleno for Prader-Willi therapySoleno Therapeutics Inc. (NASDAQ:SLNO...
...tablets to support an NDA submission to treat Prader-Willi syndrome. Yescarta gains third indicationGilead Sciences Inc. (NASDAQ:GILD...
BioCentury | Mar 6, 2021
Management Tracks

Winter to lead BeiGene’s European commerical ops; plus Dyne, Axcella, Prometheus and more

...By BioCentury Staff BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) hired Gerwin Winter as SVP and head of commercial...
...and head of Europe at Portola Pharmaceuticals Inc. before its acquisition by Alexion Pharmaceuticals Inc. (NASDAQ:ALXN...
...Inc. (NASDAQ:AXLA) as president of R&D. Schecter previously served as CMO at Selecta Biosciences Inc. (NASDAQ:SELB...
BioCentury | Mar 6, 2021
Product Development

March 5 Quick Takes: A regulatory first for Actemra; plus updates from Lilly-Incyte, Kronos, Junshi, United Therapeutics, Pfizer, Sumitomo Dainippon, Arena, Oyster Point, Azura

...endpoint in first Phase III for alopecia areataEli Lilly and Co. (NYSE:LLY) and Incyte Corp. (NASDAQ:INCY) said...
...arthritis.Kronos trial bringing MRD surrogate endpoint to AMLFollowing a meeting with FDA, Kronos Bio Inc. (NASDAQ:KRON...
...China-grown PD-1 under FDA reviewShanghai Junshi Biosciences Co. Ltd. (HKEX:1877; Shanghai:688180) and Coherus BioSciences Inc. (NASDAQ:CHRS...
BioCentury | Mar 6, 2021
Product Development

The pace of new modality approvals is picking up

...Johnson & Johnson (NYSE:JNJ) and Genmab A/S (NASDAQ:GMAB...
...Inc. (NASDAQ:PTCT), Elivaldogene autotemcel (Lenti-D) from bluebird bio Inc. (NASDAQ:BLUE...
...companies, Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and Sarepta Therapeutics Inc. (NASDAQ:SRPT...
BioCentury | Mar 6, 2021
Deals

How Bayer is building a cell and gene therapy business through deals

...$60 million collaboration with Atara Biotherapeutics Inc. (NASDAQ:ATRA...
...as joint venture with CRISPR Therapeutics AG (NASDAQ:CRSP). The...
...unit is working with Editas Medicine Inc. (NASDAQ:EDIT...
BioCentury | Mar 6, 2021
Regulation

March 5 COVID Quick Takes: Lilly mAbs clear EU hurdle; plus Adaptive authorization, Takeda pushes vaccine ahead in Japan, Aerpio therapy out of I-SPY

...Editor, And Jeff Cranmer, Executive Editor EMA’s CHMP recommended use of bamlanivimab from AbCellera Biologics Inc. (NASDAQ:ABCL...
...of progressing to severe COVID-19. FDA authorizes Adaptive T cell test for COVID-19Adaptive Biotechnologies Corp. (NASDAQ:ADPT...
...launched Feb. 23 as a laboratory-developed test (LDT).Takeda seeks Japan authorization of Moderna vaccineModerna Inc. (NASDAQ:MRNA...
Items per page:
1 - 10 of 57952
BioCentury | Mar 9, 2021
Product Development

AnaptysBio looks ahead to other indications after Phase II miss in palmoplantar pustulosis

...psoriasis (GPP), where IL-36 signaling has a clearer role in driving disease. Shares of AnaptysBio Inc. (NASDAQ:ANAB...
BioCentury | Mar 9, 2021
Politics, Policy & Law

Biopharmas ask Biden to reject compulsory licensing of COVID-19 medicines

...NASDAQ:GILD), GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), Merck & Co. Inc. (NYSE:MRK), Pfizer Inc. (NYSE:PFE), Sanofi (Euronext:SAN; NASDAQ:SNY...
BioCentury | Mar 9, 2021
Product Development

New modality deep dive; plus Sharpless speaks & Five Prime scores: a BioCentury podcast

...2017, when Kadcyla ado-trastuzumab emtansine from Roche (SIX:ROG; OTCQX:RHHBY) and Adcetris brentuximab vedotin from  Seagen Inc. (NASDAQ:SGEN...
...Executive Editor Jeff Cranmer discusses the acquisition of Five Prime Therapeutics Inc. (NASDAQ:FPRX) by Amgen Inc. (NASDAQ:AMGN...
BioCentury | Mar 8, 2021
Management Tracks

ArsenalBio bolsters team via hirings of Sirichoke, Schroer; plus Moderna, Jubilant and Synlogic

...quality head at Novartis AG (NYSE:NVS; SIX:NOVN). Schroer previously was CFO at Translate Bio Inc. (NASDAQ:TBIO...
...of tools the company thinks could overcome hurdles to cell therapy for solid tumors. Moderna Inc. (NASDAQ:MRNA...
...Rastelli was CSO at Kleo Pharmaceuticals Inc. and VP of oncology at BioXcel Therapeutics Inc. (NASDAQ:BTAI). Jubilant...
BioCentury | Mar 8, 2021
Deals

March 8 Quick Takes: Roivant to acquire Immunovant; plus Lilly-Biolojic, Soleno, Gilead, Genentech and Cara-Vifor

...By BioCentury Staff Immunovant Inc. (NASDAQ:IMVT) rose $1.88 (14%) to $15.39 on Monday after the autoimmune...
...to Biolojic equity, plus royalties.FDA requests additional trial from Soleno for Prader-Willi therapySoleno Therapeutics Inc. (NASDAQ:SLNO...
...tablets to support an NDA submission to treat Prader-Willi syndrome. Yescarta gains third indicationGilead Sciences Inc. (NASDAQ:GILD...
BioCentury | Mar 6, 2021
Management Tracks

Winter to lead BeiGene’s European commerical ops; plus Dyne, Axcella, Prometheus and more

...By BioCentury Staff BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) hired Gerwin Winter as SVP and head of commercial...
...and head of Europe at Portola Pharmaceuticals Inc. before its acquisition by Alexion Pharmaceuticals Inc. (NASDAQ:ALXN...
...Inc. (NASDAQ:AXLA) as president of R&D. Schecter previously served as CMO at Selecta Biosciences Inc. (NASDAQ:SELB...
BioCentury | Mar 6, 2021
Product Development

March 5 Quick Takes: A regulatory first for Actemra; plus updates from Lilly-Incyte, Kronos, Junshi, United Therapeutics, Pfizer, Sumitomo Dainippon, Arena, Oyster Point, Azura

...endpoint in first Phase III for alopecia areataEli Lilly and Co. (NYSE:LLY) and Incyte Corp. (NASDAQ:INCY) said...
...arthritis.Kronos trial bringing MRD surrogate endpoint to AMLFollowing a meeting with FDA, Kronos Bio Inc. (NASDAQ:KRON...
...China-grown PD-1 under FDA reviewShanghai Junshi Biosciences Co. Ltd. (HKEX:1877; Shanghai:688180) and Coherus BioSciences Inc. (NASDAQ:CHRS...
BioCentury | Mar 6, 2021
Product Development

The pace of new modality approvals is picking up

...Johnson & Johnson (NYSE:JNJ) and Genmab A/S (NASDAQ:GMAB...
...Inc. (NASDAQ:PTCT), Elivaldogene autotemcel (Lenti-D) from bluebird bio Inc. (NASDAQ:BLUE...
...companies, Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and Sarepta Therapeutics Inc. (NASDAQ:SRPT...
BioCentury | Mar 6, 2021
Deals

How Bayer is building a cell and gene therapy business through deals

...$60 million collaboration with Atara Biotherapeutics Inc. (NASDAQ:ATRA...
...as joint venture with CRISPR Therapeutics AG (NASDAQ:CRSP). The...
...unit is working with Editas Medicine Inc. (NASDAQ:EDIT...
BioCentury | Mar 6, 2021
Regulation

March 5 COVID Quick Takes: Lilly mAbs clear EU hurdle; plus Adaptive authorization, Takeda pushes vaccine ahead in Japan, Aerpio therapy out of I-SPY

...Editor, And Jeff Cranmer, Executive Editor EMA’s CHMP recommended use of bamlanivimab from AbCellera Biologics Inc. (NASDAQ:ABCL...
...of progressing to severe COVID-19. FDA authorizes Adaptive T cell test for COVID-19Adaptive Biotechnologies Corp. (NASDAQ:ADPT...
...launched Feb. 23 as a laboratory-developed test (LDT).Takeda seeks Japan authorization of Moderna vaccineModerna Inc. (NASDAQ:MRNA...
Items per page:
1 - 10 of 57952